B. Metzler Seel. Sohn & Co. Ag United Therapeutics Corp Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.53 Billion
- Q4 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in United Therapeutics Corp stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 960 shares of UTHR stock, worth $343,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
960
Previous 960
-0.0%
Holding current value
$343,200
Previous $344,000
1.74%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding UTHR
# of Institutions
723Shares Held
60.9MCall Options Held
123KPut Options Held
104K-
Wealthfront Advisers LLC18.3MShares$6.55 Billion5.38% of portfolio
-
Black Rock Inc. New York, NY5.47MShares$1.96 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$1.59 Billion0.03% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.76MShares$987 Million14.19% of portfolio
-
Wellington Management Group LLP Boston, MA2.46MShares$881 Million0.16% of portfolio
About UNITED THERAPEUTICS Corp
- Ticker UTHR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,516,300
- Market Cap $16.3B
- Description
- United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...